Further functional studies are required to gain a greater understanding of CCL20-associated signaling, demonstrate clinical impact in larger (multi-center) cohorts and discover potential new therapeutic targets, especially for advanced melanoma with resistance to ICI. The gene discussed is CCL20; the disease is melanoma.